Form 4: Allovir CFO Receives Stock Grant
Insider Transaction (Form 4)
Liisa Ann Bayko, Chief Financial Officer of Allovir, Inc., received 220,000 shares of common stock on July 20, 2026.
Summary
- Grant/award: acquired 220,000 Stock Option (Right to Buy) on July 20, 2026; holds 220,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Liisa Ann Bayko — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-20 | Grant/award | Stock Option (Right to Buy) | 220,000 | — | — | 220,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-20 | Grant/award (220,000 shares) |
Keywords
insider transaction, Form 4, KLRS, Kalaris Therapeutics, Inc., neutral, Liisa Ann Bayko
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.